Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Dementia Complex | 18 | 2015 | 102 | 3.770 |
Why?
|
| Cognition Disorders | 9 | 2017 | 233 | 1.760 |
Why?
|
| HIV Infections | 15 | 2024 | 2303 | 1.740 |
Why?
|
| HIV Seropositivity | 8 | 2018 | 190 | 1.200 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 25 | 0.920 |
Why?
|
| HIV-1 | 9 | 2020 | 706 | 0.770 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2023 | 221 | 0.690 |
Why?
|
| Puerto Rico | 10 | 2020 | 1378 | 0.660 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 162 | 0.590 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 234 | 0.580 |
Why?
|
| Neuropsychological Tests | 8 | 2024 | 259 | 0.570 |
Why?
|
| Access to Information | 1 | 2015 | 13 | 0.540 |
Why?
|
| Humans | 40 | 2024 | 37093 | 0.520 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 49 | 0.510 |
Why?
|
| Cell Movement | 1 | 2018 | 571 | 0.500 |
Why?
|
| Models, Biological | 1 | 2018 | 677 | 0.500 |
Why?
|
| Exercise | 1 | 2020 | 613 | 0.490 |
Why?
|
| Adult | 23 | 2020 | 11712 | 0.480 |
Why?
|
| Female | 29 | 2024 | 20969 | 0.460 |
Why?
|
| Macrophages | 5 | 2017 | 439 | 0.460 |
Why?
|
| Insulin Resistance | 1 | 2015 | 184 | 0.430 |
Why?
|
| Apolipoproteins | 1 | 2012 | 22 | 0.430 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 20 | 0.420 |
Why?
|
| DNA, Viral | 1 | 2013 | 304 | 0.410 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 147 | 0.400 |
Why?
|
| Learning | 1 | 2012 | 117 | 0.400 |
Why?
|
| Cognition | 3 | 2024 | 398 | 0.390 |
Why?
|
| Middle Aged | 18 | 2024 | 10129 | 0.390 |
Why?
|
| HIV | 2 | 2013 | 98 | 0.390 |
Why?
|
| Proteomics | 6 | 2017 | 325 | 0.380 |
Why?
|
| Puerperal Disorders | 1 | 2010 | 6 | 0.370 |
Why?
|
| Basilar Artery | 1 | 2010 | 12 | 0.370 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 55 | 0.360 |
Why?
|
| Education, Distance | 1 | 2010 | 44 | 0.350 |
Why?
|
| Thrombosis | 1 | 2010 | 63 | 0.340 |
Why?
|
| Dementia | 1 | 2010 | 131 | 0.340 |
Why?
|
| Monocytes | 6 | 2013 | 257 | 0.330 |
Why?
|
| Research | 1 | 2007 | 163 | 0.270 |
Why?
|
| Protein Array Analysis | 2 | 2004 | 25 | 0.250 |
Why?
|
| Hippocampus | 2 | 2022 | 561 | 0.250 |
Why?
|
| Cohort Studies | 6 | 2024 | 1492 | 0.240 |
Why?
|
| Memory | 3 | 2012 | 170 | 0.230 |
Why?
|
| Neurology | 2 | 2013 | 12 | 0.220 |
Why?
|
| Proteome | 2 | 2017 | 144 | 0.220 |
Why?
|
| Flumazenil | 1 | 2000 | 1 | 0.190 |
Why?
|
| Midazolam | 1 | 2000 | 3 | 0.190 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 26 | 0.190 |
Why?
|
| Smoking | 1 | 2007 | 940 | 0.190 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 19 | 0.190 |
Why?
|
| HIV Antibodies | 1 | 2020 | 30 | 0.190 |
Why?
|
| Glycopeptides | 1 | 2020 | 12 | 0.180 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 103 | 0.180 |
Why?
|
| Anthropometry | 1 | 2020 | 97 | 0.180 |
Why?
|
| Electroencephalography | 1 | 2000 | 116 | 0.180 |
Why?
|
| Cells, Cultured | 3 | 2018 | 1518 | 0.170 |
Why?
|
| Disease Progression | 3 | 2013 | 601 | 0.170 |
Why?
|
| Longitudinal Studies | 5 | 2013 | 885 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 2721 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2026 | 0.160 |
Why?
|
| Quality of Life | 2 | 2013 | 481 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 2 | 2007 | 18 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2017 | 10 | 0.150 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 66 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 253 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2018 | 400 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 935 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2018 | 894 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2017 | 291 | 0.130 |
Why?
|
| Lymphocytes | 2 | 2013 | 118 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 26 | 0.130 |
Why?
|
| Viral Load | 4 | 2013 | 312 | 0.120 |
Why?
|
| Public Health | 1 | 2018 | 372 | 0.120 |
Why?
|
| Male | 9 | 2024 | 20025 | 0.120 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 6 | 0.120 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2013 | 4 | 0.120 |
Why?
|
| Sampling Studies | 1 | 2013 | 61 | 0.120 |
Why?
|
| 14-3-3 Proteins | 1 | 2013 | 22 | 0.120 |
Why?
|
| Epilepsy | 1 | 2013 | 43 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 448 | 0.110 |
Why?
|
| Fatigue | 1 | 2013 | 83 | 0.110 |
Why?
|
| Cystatin B | 1 | 2013 | 7 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2013 | 26 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2012 | 14 | 0.110 |
Why?
|
| Gene Expression | 2 | 2013 | 674 | 0.110 |
Why?
|
| Internet | 2 | 2012 | 211 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2013 | 39 | 0.100 |
Why?
|
| Reaction Time | 1 | 2012 | 143 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 191 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 71 | 0.100 |
Why?
|
| Alleles | 1 | 2012 | 321 | 0.100 |
Why?
|
| Psychometrics | 2 | 2017 | 318 | 0.100 |
Why?
|
| Prevalence | 2 | 2024 | 1455 | 0.090 |
Why?
|
| Pharmacology | 1 | 2010 | 5 | 0.090 |
Why?
|
| Thrombophilia | 1 | 2010 | 4 | 0.090 |
Why?
|
| Allergy and Immunology | 1 | 2010 | 11 | 0.090 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 5 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 6741 | 0.090 |
Why?
|
| Neurosciences | 1 | 2010 | 28 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 610 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 628 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2007 | 189 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1130 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2012 | 928 | 0.080 |
Why?
|
| Antioxidants | 2 | 2010 | 416 | 0.080 |
Why?
|
| Mentors | 1 | 2010 | 127 | 0.080 |
Why?
|
| Health Status | 1 | 2012 | 380 | 0.080 |
Why?
|
| Language | 1 | 2010 | 157 | 0.080 |
Why?
|
| Focus Groups | 1 | 2010 | 348 | 0.080 |
Why?
|
| Catalase | 1 | 2008 | 109 | 0.080 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 111 | 0.080 |
Why?
|
| Intelligence Tests | 1 | 2007 | 7 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 155 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 2379 | 0.080 |
Why?
|
| ROC Curve | 1 | 2007 | 138 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2007 | 37 | 0.070 |
Why?
|
| Hawaii | 1 | 2013 | 1929 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2006 | 6 | 0.070 |
Why?
|
| Women's Health | 1 | 2007 | 145 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 136 | 0.070 |
Why?
|
| Minority Groups | 1 | 2010 | 596 | 0.060 |
Why?
|
| Algorithms | 1 | 2007 | 465 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 626 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2007 | 1378 | 0.060 |
Why?
|
| Cyclohexanes | 1 | 2023 | 30 | 0.060 |
Why?
|
| Heroin | 1 | 2002 | 13 | 0.050 |
Why?
|
| Narcotics | 1 | 2002 | 32 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 86 | 0.050 |
Why?
|
| California | 1 | 2024 | 476 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2017 | 550 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2002 | 77 | 0.050 |
Why?
|
| Depression | 1 | 2007 | 712 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2017 | 859 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 245 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2020 | 20 | 0.050 |
Why?
|
| Cricetulus | 1 | 2020 | 80 | 0.050 |
Why?
|
| CHO Cells | 1 | 2020 | 124 | 0.050 |
Why?
|
| Glycosylation | 1 | 2020 | 100 | 0.050 |
Why?
|
| Cricetinae | 1 | 2020 | 238 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 103 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 109 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 515 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 262 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 642 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2007 | 78 | 0.040 |
Why?
|
| Microwaves | 1 | 2017 | 24 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2017 | 5 | 0.040 |
Why?
|
| Magnetics | 1 | 2017 | 36 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4268 | 0.040 |
Why?
|
| Adolescent | 2 | 2013 | 5363 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 142 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 260 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2015 | 4 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 155 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 182 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 238 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 90 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 730 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1568 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 922 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hospitalization | 1 | 2017 | 388 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 77 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 93 | 0.030 |
Why?
|
| Ceramides | 1 | 2013 | 42 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 191 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 400 | 0.030 |
Why?
|
| Outpatients | 1 | 2012 | 33 | 0.030 |
Why?
|
| Cholesterol | 1 | 2013 | 205 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 399 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 2010 | 11 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 9 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 67 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 49 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2010 | 42 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 66 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 513 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 149 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 168 | 0.020 |
Why?
|
| Complement C3 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 61 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 201 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 15081 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 69 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 223 | 0.020 |
Why?
|
| Glioma | 1 | 2007 | 79 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 181 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 523 | 0.020 |
Why?
|
| Neurons | 2 | 2003 | 1175 | 0.020 |
Why?
|
| Virus Replication | 1 | 2007 | 278 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 3562 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1180 | 0.020 |
Why?
|
| Phenotype | 1 | 2007 | 689 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 5 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 33 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 2002 | 35 | 0.010 |
Why?
|
| United States | 1 | 2013 | 4223 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 53 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2002 | 55 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 562 | 0.010 |
Why?
|
| Dopamine | 1 | 2002 | 245 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2231 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 587 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2003 | 420 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 1346 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3483 | 0.010 |
Why?
|